title: Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report.
abstract: OBJECTIVE
  The feasibility and activity of an intensive chemoradiotherapeutic scheme for patients with locally advanced squamous cell head and neck cancers were tested in a single institution Phase II pilot study.
  
  
  METHODS
  Between January 1990 and February 1992, 40 patients were entered into this trial. The treatment protocol consisted of split hyperfractionated accelerated radiation therapy (SHART), 1.6 Gy per fraction given twice per day to a total dose of 64-67.2 Gy for a total of 6 weeks with a 2-week gap, and cisplatin (20 mg/sqm/Days 1 to 5, in continuous perfusion) concomitantly.
  
  
  RESULTS
  All of the 40 patients are evaluable for response and survival. Toxicity was significant, but tolerable. A complete tumor response to this treatment was achieved by 37 patients (92.5%). With a minimal follow-up of 22 months (median 30 months) there have been 16 local relapses and 19 patients have died, 2 without tumor. The projected 2- and 3-year overall survival rates are 64% (confidence interval (CI) 95%, 49-79%) and 47%, respectively. The 2-year local control probability has been 56% (CI 95%, 39-73%).
  
  
  CONCLUSIONS
  This treatment obtains a high rate of complete responses with increased acute toxicity but tolerable late effects. Preliminary results are encouraging for laryngeal neoplasms. A longer follow-up is needed to evaluate the impact of this treatment on patient survival.
authors.affiliation: Department of Oncology, Hospital de Navarra, Pamplona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Arias
authors.forename: M A
authors.initials: MA
authors.lastname: Domínguez
authors.forename: J J
authors.initials: JJ
authors.lastname: Illarramendi
authors.forename: E
authors.initials: E
authors.lastname: Martínez
authors.forename: M
authors.initials: M
authors.lastname: Tejedor
authors.forename: S
authors.initials: S
authors.lastname: Domínguez
authors.forename: M
authors.initials: M
authors.lastname: Dueñas
authors.forename: E
authors.initials: E
authors.lastname: Villafranca
authors.forename: F
authors.initials: F
authors.lastname: Elcarte
authors.forename: S
authors.initials: S
authors.lastname: Miquéliz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004273:DNA, Neoplasm / Q000032:analysis; D005240:Feasibility Studies; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010610:Pharyngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D010865:Pilot Projects; D011003:Ploidies; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm